文献速递免疫规划妇幼与学校卫生

HPV疫苗接种状态与性传播感染结局的关联:美国18-35岁有性行为史女性的横断面分析

Association between human papillomavirus vaccine status and sexually transmitted infection outcomes among females aged 18-35 with a history of sexual activity in the United States: A population survey-based cross-sectional analysis.
PubMed 文献 · Vaccine · 2020-11-22

基于2013-2014及2015-2016年美国NHANES调查中1050名18-35岁有性行为史的女性,分析HPV疫苗接种与实验室确诊STI及疫苗型HPV的关联。结果显示接种与任何STI无关联(aOR 0.67,95%CI 0.38-1.20),疫苗型HPV风险降低61%(aOR 0.39,95%CI 0.19-0.83),但常规推荐年龄11-12岁接种率仅6.1%。

要点

  • HPV疫苗接种与实验室确诊STI无关联,不支持性风险补偿假说
  • 接种者疫苗型HPV感染风险降低61%(aOR 0.39)
  • 仅6.1%在常规推荐年龄11-12岁接种,65.7%在性 debut 后接种

核心结论

  • 在有性行为史的女性中,HPV疫苗接种对疫苗型HPV具有保护作用,且与实验室确诊STI无关。
  • 常规推荐年龄接种率低,需加强性 debut 前HPV疫苗接种推广。

研究设计与样本

  • 基于美国国家健康与营养调查(NHANES)2013-2014和2015-2016周期的横断面分析。
  • 纳入1050名18-35岁有性行为史且数据完整的女性,总调查参与者20146人。
  • 采用调查加权logistic回归、倾向评分模型和逆概率加权进行敏感性分析。

主要发现

  • 325名(31.8%)有性行为史的女性接种过HPV疫苗,其中22名(6.1%)在11-12岁常规推荐年龄接种,65.7%在自报性 debut 后接种。
  • 接种者中3.8%有实验室确诊STI,3.5%有疫苗型HPV。
  • HPV疫苗接种与任何STI无关联(aOR 0.67,95%CI 0.38-1.20)。
  • 接种者疫苗型HPV(6/11/16/18)风险降低61%(aOR 0.39,95%CI 0.19-0.83)。
  • 倾向评分敏感性分析结果与主要发现相似。

临床怎么用

  • 应着力在性 debut 前推广HPV疫苗接种,以提高常规推荐年龄接种率。
  • 接种HPV疫苗未增加STI风险,可据此回应关于性风险补偿的疫苗犹豫。

局限性

  • 结果可能受报告偏倚影响。
  • 为横断面分析,无法确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current human papillomavirus (HPV) vaccine coverage in the United States (in 2019, 66-70%), remains below the Healthy People 2020 coverage goal of 80%. HPV vaccine misinformation, including parental concerns of sexual risk-compensation influence vaccine uptake. We examined the association between HPV vaccination and sexually transmitted infection (STI) outcomes. METHODS: Of the 20,146 participants from 2013 to 2014 and 2015-2016 cycles of the National Health and Nutrition Examination Survey, 1050 females aged 18-35 with a history of sexual activity had complete case data. Roa-Scott Chi-squared and F-tests assessed survey-weighted socio-demographic differences between vaccinated and unvaccinated participants. Weighted logistic regression assessed crude and adjusted associations between self-reported HPV vaccination (none vs. ≥ 1dose) and lab-confirmed STIs (trichomonas and chlamydia) and vaccine-type HPV (6/11/16/18). As a sensitivity analysis, we conducted weighted-propensity score (PS) models and inverse probability weighting by vaccination status. PS and logistic regression were estimated through survey-weighted logistic regression on variables including race, education, income, marital status, US citizenship, cycle year and age. RESULTS: Overall, 325 (31.8%) females with a history of sexual activity were HPV vaccinated, of which 22 (6.1%) received the vaccine at the routine-recommended ages of 11-12, 65.7% were vaccinated after their self-reported sexual debut, 3.8% had a lab-confirmed STI and 3.5% had vaccine-type HPV. There was no association between HPV vaccination and any STIs (adjusted odds ratio [aOR] 0.67, 95%CI:0.38-1.20), and vaccinated participants had 61% reduced odds of vaccine-type HPV (vs. unvaccinated; aOR 0.39, 95%CI:0.19-0.83). Results from the PS sensitivity analysis were similar to the main findings. CONCLUSION: Among females who reported a history of sexual activity, HPV vaccination status was protective against vaccine-type HPV and not associated with lab-based STI outcomes. Although findings may be susceptible to reporting bias, results indicating low vaccine uptake at routine-recommended ages requires additional efforts promoting HPV vaccination before sexual-debut.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Closson K, Karim ME, Sadarangani M, et al. Association between human papillomavirus vaccine status and sexually transmitted infection outcomes among females aged 18-35 with a history of sexual activity in the United States: A population survey-based cross-sectional analysis. Vaccine. 2020. PMID: 33239227. doi:10.1016/j.vaccine.2020.10.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。